Curebase nabs $15M for siteless trials that revolve 'around the patient's lifestyle'

Curebase has raised a $15 million series A for a new approach to decentralized trials that goes beyond the current drop of virtual trial platforms.

Straight out of the blocks, Curebase is looking to be different: Siteless trials, which use wearables, telehealth and telemedicine to help trials run from subjects’ homes, were long latent in their promise, but the COVID-19 pandemic sped up their adoption as a new way of trialing medicines and devices.

Many, including the likes of Science 37 and Medable, along with traditional CROs like PPD and LabCorp’s Covance, have also doubled down on a virtual trial platform. Curebase, however, says these only solve “narrow pieces of the problem” around a siteless system, where incorporating wearables for instance is making a trial suddenly siteless.  

Curebase says it has a bigger picture platform, and has engineered a new approach to the entire clinical trial process, enabling complex studies that “can be done completely around the patient’s lifestyle.”

Its new platform “enables first-of-their kind study designs, in which patients participate both at home and in real-world settings, with best-in-class software experiences for patients, their doctors, and for telemedicine and mobile healthcare providers,” it said in a statement.

To take this forward, the company has grabbed $15 million in a series A to boost its trial software platform and virtual research site capabilities.

RELATED: Science 37 taps a SPAC to go public, with siteless trial specialist valued at a cool $1B

The financing was led by GGV Capital with participation from Xfund, Bold Capital and several other institutional funds, and brings the total raised to $19M. Jeff Richards, managing partner at GGV Capital, joins the firm’s board.

“At GGV we look for companies that are redefining massive categories by building ambitious, ground-up software platforms,” said Richards. The $50 billion clinical trial industry is clearly about to transform itself, and Curebase has a vision to reinvent the entire ecosystem to reach any patient, anywhere.

“With a small amount of capital the team has already built a comprehensive software platform that is better than anything the multi-billion dollar incumbents have managed to create, and have signed up some of the top drug companies and CROs in the world as customers. With this significant $15M funding I think they will scale incredibly quickly and change the industry.”

During the pandemic, Curebase said operated six different COVID studies using community-based “pop-up drive-through testing sites” across the country, turning them into clinical data collection machines at scale.

It also taps doctors to supply ultrasounds, colonoscopy records and other data categories, something it says has not been done before in clinical trials.

“We are currently running clinical trial designs that most researchers think won’t be possible for another 5 years,” said Tom Lemberg, founder and CEO at Curebase.

“This is research where any patient can sign up at home and collect data whenever they go to their own doctor. We’re doing it in women’s health, cancer diagnostics, GI, and many other areas. Our software and our novel virtual site framework is already combining elements of home-based research, telemedicine research, real-world data, and clinical research as a care option in ways that would surprise a lot of clinical operations leaders in the industry.”

Media contact:
media@curebase.com

Related Links:

Original Article

SOURCE Fierce Biotech

https://www.curebase.com

Press Releases

See More

Article Title

It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing.

Entire article

Article Title

It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing.

Entire article

Remote Care Powered CURE-19 Platform Enables At Home COVID-19 Clinical Trials

Curebase launches the CURE-19 Platform to provide a resource for researchers seeking to better understand COVID-19 as the pandemic begins

Entire article

Curebase Secures Jane Myles as Vice President of Clinical Trial Innovation

Curebase, a company committed to democratizing access to clinical studies through decentralized clinical trials, has named tenured clinical research expert Jane Myles as vice president of clinical trial innovation

Entire article

Introducing ‘BYOP’ clinical trials

The company Curebase is promoting the concept of 'bring-your-own-physician' clinical trials.

Entire article

Cofactor Genomics Begins Multi-Site Clinical Trial for Immunotherapy Prediction Assay

NEW YORK – Cofactor Genomics said Tuesday that it has commenced the first multicenter clinical trial of its OncoPrism immunotherapy response prediction assay, an RNA-based test developed using the company's proprietary immune modeling technology.

Entire article

Startups Cash In as Venture Funding for Digital Health Rises

The success of Doximity, which went public in June and now has a market capitalization around $8.87 billion, and other digital-health startups have encouraged venture investment.

Entire article

Preliminary Outcomes of a Digital Therapeutic Intervention for Smoking Cessation in Adult Smokers: Randomized Controlled Trial

Tobacco smoking remains the leading cause of preventable death and disease worldwide. Digital interventions delivered through smartphones offer a promising alternative to traditional methods, but little is known about their effectiveness.

Entire article

CLM tests drug plus digital combo for high blood pressure

UK biotech Closed Loop Medicine (CLM) has started recruiting patients into a trial that will test whether a drug linked to a smartphone app can improve treatment for hypertension.

Entire article

Non-Traditional Clinical Trial Sites Powered by the Curebase System Support Emergency Use Authorization of New Rapid COVID-19 Test

Operationalizing drive-through COVID testing locations as clinical research sites provided a safe and convenient way to enroll and consent potential participants in key diagnostic validation study

Entire article

Curebase, InBios Announce Results of Virtual Clinical Trial of InBios COVID-19 Rapid Detection Test Using Curebase Platform

Study demonstrates efficacy of InBios diagnostics test, Curebase decentralized trials platform

Entire article

Curebase Names Paul Donnelly as Senior Vice President of Enterprise Strategy

Industry veteran brings more than two decades of success building healthcare companies

Entire article

Curebase, Adaptive Biotechnologies Announce Collaboration to Expand Clinical Study Access

Initial study will validate effectiveness of Adaptive's Lyme disease immune detection test

Entire article

Press Releases

See more

Introducing ‘BYOP’ clinical trials

The company Curebase is promoting the concept of 'bring-your-own-physician' clinical trials.

Entire article

Curebase Names Paul Donnelly as Senior Vice President of Enterprise Strategy

Industry veteran brings more than two decades of success building healthcare companies

Entire article

Startups Cash In as Venture Funding for Digital Health Rises

The success of Doximity, which went public in June and now has a market capitalization around $8.87 billion, and other digital-health startups have encouraged venture investment.

Entire article

Curebase, InBios Announce Results of Virtual Clinical Trial of InBios COVID-19 Rapid Detection Test Using Curebase Platform

Study demonstrates efficacy of InBios diagnostics test, Curebase decentralized trials platform

Entire article

Curebase nabs $15M for siteless trials that revolve 'around the patient's lifestyle'

Curebase has raised a $15 million series A for a new approach to decentralized trials that goes beyond the current drop of virtual trial platforms.

Entire article

Cofactor Genomics Begins Multi-Site Clinical Trial for Immunotherapy Prediction Assay

NEW YORK – Cofactor Genomics said Tuesday that it has commenced the first multicenter clinical trial of its Onco Prism immunotherapy response prediction assay, an RNA-based test developed using the company's proprietary immune modeling technology.

Entire article

Non-Traditional Clinical Trial Sites Powered by the Curebase System Support Emergency Use Authorization of New Rapid COVID-19 Test

Operationalizing drive-through COVID testing locations as clinical research sites provided a safe and convenient way to enroll and consent potential participants in key diagnostic validation study

Entire article

CLM tests drug plus digital combo for high blood pressure

UK biotech Closed Loop Medicine (CLM) has started recruiting patients into a trial that will test whether a drug linked to a smartphone app can improve treatment for hypertension.

Entire article

Preliminary Outcomes of a Digital Therapeutic Intervention for Smoking Cessation in Adult Smokers: Randomized Controlled Trial

Tobacco smoking remains the leading cause of preventable death and disease worldwide. Digital interventions delivered through smartphones offer a promising alternative to traditional methods, but little is known about their effectiveness.

Entire article

Curebase Secures Jane Myles as Vice President of Clinical Trial Innovation

Curebase, a company committed to democratizing access to clinical studies through decentralized clinical trials, has named tenured clinical research expert Jane Myles as vice president of clinical trial innovation

Entire article

Curebase, Adaptive Biotechnologies Announce Collaboration to Expand Clinical Study Access

Initial study will validate effectiveness of Adaptive's Lyme disease immune detection test

Entire article

Introducing ‘BYOP’ clinical trials

The company Curebase is promoting the concept of 'bring-your-own-physician' clinical trials.

Entire article

Curebase Names Paul Donnelly as Senior Vice President of Enterprise Strategy

Industry veteran brings more than two decades of success building healthcare companies

Entire article

Startups Cash In as Venture Funding for Digital Health Rises

The success of Doximity, which went public in June and now has a market capitalization around $8.87 billion, and other digital-health startups have encouraged venture investment.

Entire article

Curebase, InBios Announce Results of Virtual Clinical Trial of InBios COVID-19 Rapid Detection Test Using Curebase Platform

Study demonstrates efficacy of InBios diagnostics test, Curebase decentralized trials platform

Entire article

Curebase nabs $15M for siteless trials that revolve 'around the patient's lifestyle'

Curebase has raised a $15 million series A for a new approach to decentralized trials that goes beyond the current drop of virtual trial platforms.

Entire article

Cofactor Genomics Begins Multi-Site Clinical Trial for Immunotherapy Prediction Assay

NEW YORK – Cofactor Genomics said Tuesday that it has commenced the first multicenter clinical trial of its OncoPrism immunotherapy response prediction assay, an RNA-based test developed using the company's proprietary immune modeling technology.

Entire article

Non-Traditional Clinical Trial Sites Powered by the Curebase System Support Emergency Use Authorization of New Rapid COVID-19 Test

Operationalizing drive-through COVID testing locations as clinical research sites provided a safe and convenient way to enroll and consent potential participants in key diagnostic validation study

Entire article

CLM tests drug plus digital combo for high blood pressure

UK biotech Closed Loop Medicine (CLM) has started recruiting patients into a trial that will test whether a drug linked to a smartphone app can improve treatment for hypertension.

Entire article

Preliminary Outcomes of a Digital Therapeutic Intervention for Smoking Cessation in Adult Smokers: Randomized Controlled Trial

Tobacco smoking remains the leading cause of preventable death and disease worldwide. Digital interventions delivered through smartphones offer a promising alternative to traditional methods, but little is known about their effectiveness.

Entire article

Remote Care Powered CURE-19 Platform Enables At Home COVID-19 Clinical Trials

Curebase launches the CURE-19 Platform to provide a resource for researchers seeking to better understand COVID-19 as the pandemic begins

Entire article

Our latest news

It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
335 S Van Ness Ave, San Francisco, CA,
94103-3627, United States